{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:11:04Z","timestamp":1783606264410,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.01.022","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T09:58:31Z","timestamp":1738058311000},"page":"e510-e512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Rami","family":"Kotb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Geirnaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Kasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Minuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Landego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.01.022_bib0001","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.022_bib0002","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.01.022_bib0003","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.01.022_bib0004","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.022_bib0005","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2023-190168","volume":"142","author":"Kotb","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.01.022_bib0006","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.01.022_bib0007","unstructured":"FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. (2024). Accessed: November 11, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-isatuximab-irfc-bortezomib-lenalidomide-a"},{"key":"10.1016\/j.clml.2025.01.022_bib0008","unstructured":"Sarclisa (isatuximab) [prescribing information: Sanofi; October 2024. Accessed: November 11, 2024 Available at: https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf."},{"issue":"11","key":"10.1016\/j.clml.2025.01.022_bib0009","doi-asserted-by":"crossref","first-page":"e70041","DOI":"10.1002\/hem3.70041","article-title":"30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: results of a Phase 1b study analysis","volume":"8","author":"Ocio","year":"2024","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.clml.2025.01.022_bib0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/ejh.14180","volume":"112","author":"Ayto","year":"2024","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.022_bib0011","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3324\/haematol.2023.283073","article-title":"Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis","volume":"109","author":"Facon","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.01.022_bib0012","unstructured":"SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM (IRAKLIA). Clinicaltrials.gov. Updated November 14, 2024. Accessed January 9, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05405166."},{"issue":"6","key":"10.1016\/j.clml.2025.01.022_bib0013","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clml.2024.02.004","article-title":"Recent developments in convenience of administration of the anti-CD38 antibody isatuximab: subcutaneous delivery and fast intravenous infusion in patients with multiple myeloma","volume":"24","author":"Quach","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:50:41Z","timestamp":1749477041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000394"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}